# Cytek Biosciences (CTKB) — Analyst Forecast

CTKB · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ctkb/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 2 | 2 | 0 | 4 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| May 13, 2026 | Stephens & Co. | Maintained | Overweight | $4.75 |
| May 12, 2026 | Morgan Stanley | Maintained | Equal-Weight | $5.50 |
| Jan 8, 2026 | TD Cowen | Maintained | Buy | $5.00 |
| Nov 11, 2025 | Piper Sandler | Maintained | Overweight | $7.50 |
| May 28, 2025 | Morgan Stanley | Maintained | Equal-Weight | $7.00 |
| May 12, 2025 | Goldman Sachs | Maintained | Sell | $3.00 |
| Mar 19, 2025 | Stephens & Co. | Maintained | Overweight | $6.00 |
| Mar 4, 2025 | Piper Sandler | Maintained | Overweight | $8.00 |
| Nov 11, 2024 | Piper Sandler | Maintained | Overweight | $8.50 |
| Aug 13, 2024 | Piper Sandler | Maintained | Overweight | $8.00 |
| May 13, 2024 | Piper Sandler | Maintained | Overweight | $8.50 |
| Mar 6, 2024 | Piper Sandler | Maintained | Overweight | $10.00 |
| Feb 29, 2024 | Goldman Sachs | Maintained | Buy | $10.00 |
| Dec 14, 2023 | Stephens & Co. | Initiated Coverage | Overweight | $9.00 |
| Nov 9, 2023 | Morgan Stanley | Maintained | Equal-Weight | $7.00 |
| Oct 24, 2023 | Morgan Stanley | Maintained | Equal-Weight | $8.00 |
| Oct 16, 2023 | Piper Sandler | Maintained | Overweight | $10.00 |
| Jul 19, 2023 | Raymond James | Initiated Coverage | Market Perform | — |
| May 11, 2023 | Morgan Stanley | Maintained | Equal-Weight | $13.00 |
| May 10, 2023 | Goldman Sachs | Maintained | Buy | $12.00 |

## Frequently Asked Questions

### Is CTKB a buy, sell, or hold?

Analysts covering Cytek Biosciences currently average a Buy rating: 2 buy, 2 hold and 0 sell, from 4 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on CTKB?

On May 13, 2026, Stephens & Co. maintained Cytek Biosciences at Overweight with a price target of $4.75.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).